Dermwiz Lite app for iPhone and iPad

Dermwiz Lite is a free, fully functional version of Dermwiz™ limited to 250 common and classical skin diseases. To access Dermwiz on the web and to be informed of future releases, please register at www.dermwiz.com.

Dermwiz™ is a medical diagnostic decision support system designed to assist physicians and other health professionals diagnose skin diseases. It describes mainly inflammatory skin diseases (rashes) and their neoplastic mimics. Dermwiz is built around a searchable database that provides a list of diseases matching search criteria selected by the user from a menu covering clinical, epidemiological and pathological aspects of diseases. Users may also search diseases by name. Each disease is described succinctly; references, both in popular textbooks and online, are also provided.

Most health care workers familiar with skin diseases will find Dermwiz easy to use and fast. Instructions on how to use Dermwiz are available at www.dermwiz.com .

Dermwiz is meant to assist, not replace, trained professionals. Dermwiz should be used only by qualified and licensed health professionals. Like all computer programs, Dermwiz lacks human intuition and judgment and, therefore, cannot establish a diagnosis or a treatment plan for a given patient. All information obtained from Dermwiz must be evaluated critically by the user.

Patients should not use Dermwiz. The information provided by Dermwiz does not constitute, and is not intended to replace, professional advice, judgment or diagnosis nor to substitute for professional training. Not all diseases are listed or described in Dermwiz. The best diagnosis for a given patient may not be listed by Dermwiz.

Dermwiz is a product of, and is entirely owned by, Cogniwiz Diagnostic Decisions Inc. (doing business as Cogniwiz Inc.) located in Moncton, Canada. Dermwiz™ is a registered trademark owned by Cogniwiz Inc. Dermwiz is edited by Dr. Emmanuel Maicas, Ph.D., MD, FRCPSC, Pathologist.

Dermwiz has been developed over more than fifteen years and will continues to evolve. Your feedback, suggestions and comments are always welcomed. Please write to [email protected]